Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension

Chest

Volumn 141, Issue 1, 2012, Pages 20-26

  Gabler, Nicole B ^a   French, Benjamin ^a   Strom, Brian L ^a   Liu, Ziyue ^b   Palevsky, Harold I ^a   Taichman, Darren B ^a   Kawut, Steven M ^a   Halpern, Scott D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; SITAXSENTAN;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; DRUG RESPONSE; EXERCISE TEST; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SIX MINUTE WALK DISTANCE;

EID: 84855440266     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0404     Document Type: Article

References (35)

1. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1-22. (Pubitemid 46330548)
2. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661-687. (Pubitemid 40143102)
3. Harch S, Whitford H, McLean C. Failure of medical therapy in pulmonary arterial hypertension. Is there an alternative diagnosis? Chest. 2009;135(6):1462-1469.
4. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. Circulation. 2009;119 (16):2250-2294.
5. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353(9147):133-138. (Pubitemid 29088093)
6. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114(6):464-469.
7. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120(5):1562-1569. (Pubitemid 33078473)
8. Miyauchi T, Yanagisawa M, Iida K, et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J. 1992;123(4 Pt 1):1092-1093.
9. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118(6):429-432. (Pubitemid 23081052)
10. Stauffer BL, Westby CM, Greiner JJ, Van Guilder GP, Desouza CA. Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R261-R265.
11. Treiber FA, Kapuku GK, Davis H, Pollock JS, Pollock DM. Plasma endothelin-1 release during acute stress: role of ethnicity and sex. Psychosom Med. 2002;64(5):707-713.
12. Campia U, Cardillo C, Panza JA. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation. 2004;109(25):3191-3195.
13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. (Pubitemid 34984638)
14. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123. (Pubitemid 32971843)
15. Galiè N, Olschewski H, Oudiz RJ, et al;Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010- 3019.
16. Barst RJ, Langleben D, Frost A, et al.;STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441-447. (Pubitemid 38187114)
17. Barst RJ, Langleben D, Badesch D, et al.;STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-2056.
18. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788. (Pubitemid 34925627)
19. Dewey FE, Rosenthal D, Murphy DJ Jr, Froelicher VF, Ashley EA. Does size matter? Clinical applications of scaling cardiac size and function for body size. Circulation. 2008;117(17):2279-2287.
20. Klebanoff MA, Cole SR. Use of multiple imputation in the epidemiologic literature. Am J Epidemiol. 2008;168(4):355-357
21. Sakao S, Tanabe N, Tatsumi K. The estrogen paradox in pulmonary arterial hypertension [published retraction appears in Am J Physiol Lung Cell Mol Physiol. 2011;300(3):L508]. Am J Physiol Lung Cell Mol Physiol. 2010; 299 (4):L435- L438.
22. Sweeney L, Voelkel NF. Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res. 2009;14(10):433-442.
23. Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752-759.
24. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
25. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28(4):652-655. (Pubitemid 26327964)
26. Davis KK, Lilienfeld DE, Doyle RL. Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. J Natl Med Assoc. 2008;100(1):69-72. (Pubitemid 351224259)
27. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005;95(2):199-203. 28. Lederer DJ, Arcasoy SM, Barr RG, et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant. 2006;6(10):2436-2442. (Pubitemid 44359431)
28. Lederer DJ, Caplan-Shaw CE, O'Shea MK, et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant. 2006;6(2):398-403. (Pubitemid 43382178)
29. Spertus JA, Jones PG, Masoudi FA, Rumsfeld JS, Krumholz HM. Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med. 2009;150(5):314-324.
30. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365(9455):256-265. (Pubitemid 40138020)
31. Ioannidis JPA, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol. 1998;148(11):1117-1126. (Pubitemid 28562172)
32. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298(10):1209-1212. (Pubitemid 47403108)
33. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood). 2005;24(6):1571-1581.
34. Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med. 2007;28(1):75-89.
35. Marshall SW. Power for tests of interaction: effect of raising the type I error rate. Epidemiol Perspect Innov. 2007;4 :4.